The Future of Anti-EGFR Therapy? – Part 2

In “The Future of Anti-EGFR Therapy – Part 1” we covered some of the major ways anti-EGFR therapeutic antibodies work (“blocking the gas pedal” and “flagging the immune system”) – but there are certainly areas for improvement! Since approximately half of Stage IV colorectal cancer…

Read Full Post

Colorectal Cancer News in Brief: June 12

Briefs are back this week after a couple of weeks off for the ASCO meeting, and we review research that finds small liver mets don’t affect survival after treatment for peritoneal carcinomatosis.  A gene has been found  that’s necessary for Celebrex to control new colon…

Read Full Post